3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
4
OTHER
2
OTHER_GOV
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
1
Conditions
Pain
14
Neoplasms
6
Colonic Neoplasms
5
Agnosia
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Cancer Pain
4
Breast Neoplasms
4
Rectal Neoplasms
3
Prostatic Neoplasms
3
Pain, Postoperative
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pleural Effusion, Malignant
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Diverticulosis, Colonic
2
Chronic Pain
2
Breakthrough Pain
2
post laminectomy syndrome
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombocythemia, Essential
1
Terminal Cancer
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Interventions
Fentanyl
2
Urinary Catheterization
1
Patient Positioning
1
Passive Cutaneous Anaphylaxis
1
Morphine
1
Methadone
1
Infusions, Intravenous
1
Gastrostomy
1
Administration, Sublingual
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Breakthrough Pain
×
Fentanyl
×
Clear all
NCT03809455
2020-04-22
FARADI
UNICANCER
Phase 2
Withdrawn
NCT02869321
2019-05-13
ANTALGIP
Central Hospital, Nancy, France
Phase 4
Completed
20 enrolled